A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, Tolerability, Viral Kinetics, and Pharmacokinetics of OrallyAdministered ALS-008176 Regimens in Infants and Children Aged 1 to 36 Months Hospitalized with Respiratory Syncytial Virus

Trial Profile

A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, Tolerability, Viral Kinetics, and Pharmacokinetics of OrallyAdministered ALS-008176 Regimens in Infants and Children Aged 1 to 36 Months Hospitalized with Respiratory Syncytial Virus

Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Jan 2018

At a glance

  • Drugs Lumicitabine (Primary)
  • Indications Respiratory syncytial virus infections
  • Focus Pharmacokinetics
  • Sponsors Janssen Research & Development; Janssen-Cilag
  • Most Recent Events

    • 15 Dec 2017 Status changed from not yet recruiting to recruiting.
    • 07 Jul 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top